Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8805326 | 0.83 | AKR1B1 (0.67) | AKR1B1 | |
| SCHEMBL4390579 | 0.81 | AKR1B1 (0.44) | AKR1B1 | |
| SCHEMBL11980499 | 0.80 | MAPT (0.44) | AKR1B1KDM4EMAPTHCRTR1LMNA | |
| SCHEMBL10975404 | 0.74 | MAPT (0.51) | MAPT | |
| SCHEMBL10978203 | 0.73 | SCN9A (0.54) | MAPTALDH1A1 | |
| SCHEMBL10975222 | 0.72 | AKR1B1 (0.53) | AKR1B1 | |
| SCHEMBL11980232 | 0.71 | OPRM1 (0.45) | AKR1B1KDM4EMAPTHCRTR1LMNA | |
| SCHEMBL12314572 | 0.71 | SCN9A (0.48) | KDM4EMAPTHCRTR1LMNARAD52 | |
| SCHEMBL15314943 | 0.71 | SCN9A (0.48) | KDM4EMAPTHCRTR1LMNARAD52 | |
| SCHEMBL9384403 | 0.71 | AKR1B1 (0.57) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236963-B2 | Tricyclic spiro derivatives as CRTH2 modulators | MERCK SERONO SA (CH) | 2012-08-07 | — | — | US | disclosed |
| US-20090318486-A1 | Tricyclic spiro derivatives as CRTH2 modulators | LABORATOIRES SERONO S.A. (CH) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318486-A1 | Tricyclic spiro derivatives as CRTH2 modulators | RORB, NR3C2, NR1H2 | AKR1B1 109/4885KDM4E 4406/4885MAPT 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.